RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells

Cancer Immunology, Immunotherapy

Volumn 59, Issue 8, 2010, Pages 1173-1183

  Borkner, Lisa ^a,b   Kaiser, Andrew ^a   Van De Kasteele, Willeke ^a   Andreesen, Reinhard ^b   MacKensen, Andreas ^c   Haanen, John B ^a   Schumacher, Ton N ^a   Blank, Christian ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

B7 H1; PD 1; PD L1; SiRNA; T cell

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RETROVIRUS VECTOR; SMALL INTERFERING RNA; T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL FUNCTION; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE TRANSFER; LYMPHOMA CELL LINE; MASTOCYTOMA; MELANOMA CELL; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RNA INTERFERENCE; RNA SEQUENCE; T LYMPHOCYTE; TISSUE SPECIFICITY; TREATMENT OUTCOME; TUMOR CELL; TUMOR MICROENVIRONMENT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MELANOMA; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RETROVIRIDAE; RNA INTERFERENCE; RNA, SMALL INTERFERING; T-LYMPHOCYTES;

EID: 77953229315     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0842-0     Document Type: Article

References (30)

1. SA Rosenberg ME Dudley 2009 Adoptive cell therapy for the treatment of patients with metastatic melanoma Curr Opin Immunol 21 233 240 10.1016/j.coi.2009.03.002 1:CAS:528:DC%2BD1MXlsVCgtb8%3D 19304471
2. CH June 2007 Adoptive T cell therapy for cancer in the clinic J Clin Invest 117 1466 1476 10.1172/JCI32446 10.1172/JCI32446 1:CAS:528: DC%2BD2sXmsVWktb8%3D 17549249 (Pubitemid 46871329)
3. A Mackensen N Meidenbauer S Vogl M Laumer J Berger R Andreesen 2006 Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma J Clin Oncol 24 5060 5069 10.1200/JCO.2006.07.1100 10.1200/JCO.2006.07.1100 1:CAS:528:DC%2BD28Xht1Gnur3O 17075125 (Pubitemid 46631410)
4. C Yee JA Thompson D Byrd SR Riddell P Roche E Celis PD Greenberg 2002 Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells Proc Natl Acad Sci USA 99 16168 16173 10.1073/pnas.242600099 1:CAS:528:DC%2BD38Xps1ensLk%3D 12427970 (Pubitemid 35462767)
5. MJ Besser R Shapira-Frommer AJ Treves D Zippel O Itzhaki E Schallmach A Kubi B Shalmon I Hardan R Catane E Segal G Markel S Apter AB Nun I Kuchuk A Shimoni A Nagler J Schachter 2009 Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients J Immunother 32 415 423 10.1097/CJI. 0b013e31819c8bda 1:CAS:528:DC%2BD1MXkvVGmsbc%3D 19342963
6. C Blank J Kuball S Voelkl H Wiendl B Becker B Walter O Majdic TF Gajewski M Theobald R Andreesen A Mackensen 2006 Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro Int J Cancer 119 317 327 10.1002/ijc.21775 1:CAS:528:DC%2BD28XmsVOjtL8%3D 16482562
7. GJ Freeman AJ Long Y Iwai K Bourque T Chernova H Nishimura LJ Fitz N Malenkovich T Okazaki MC Byrne HF Horton L Fouser L Carter V Ling MR Bowman BM Carreno M Collins CR Wood T Honjo 2000 Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 1027 1034 10.1084/jem.192.7.1027 1:CAS:528: DC%2BD3cXntFSlt7o%3D 11015443
8. Y Latchman CR Wood T Chernova D Chaudhary M Borde I Chernova Y Iwai AJ Long JA Brown R Nunes EA Greenfield K Bourque VA Boussiotis LL Carter BM Carreno N Malenkovich H Nishimura T Okazaki T Honjo AH Sharpe GJ Freeman 2001 PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nat Immunol 2 261 268 10.1038/85330 1:CAS:528:DC%2BD3MXhvVaksrc%3D 11224527 (Pubitemid 33706004)
9. C Blank I Brown AC Peterson M Spiotto Y Iwai T Honjo TF Gajewski 2004 PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells Cancer Res 64 1140 1145 10.1158/0008-5472.CAN-03- 3259 1:CAS:528:DC%2BD2cXhtFCgtrs%3D 14871849 (Pubitemid 38176921)
10. H Dong SE Strome DR Salomao H Tamura F Hirano DB Flies PC Roche J Lu G Zhu K Tamada VA Lennon E Celis L Chen 2002 Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 793 800 1:CAS:528:DC%2BD38Xls12msLo%3D 12091876
11. Y Iwai M Ishida Y Tanaka T Okazaki T Honjo N Minato 2002 Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proc Natl Acad Sci USA 99 12293 12297 10.1073/pnas.192461099 1:CAS:528:DC%2BD38XntlCksL8%3D 12218188
12. C Blank TF Gajewski A Mackensen 2005 Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy Cancer Immunol Immunother 54 307 314 10.1007/s00262-004-0593-x 1:CAS:528:DC%2BD2MXhtVanuro%3D 15599732 (Pubitemid 40238924)
13. ME Keir MJ Butte GJ Freeman AH Sharpe 2008 PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 677 704 10.1146/26.021607.090331 10.1146/annurev.immunol.26.021607.090331 1:CAS:528:DC%2BD1cXltlWktrY%3D 18173375
14. R Berger R Rotem-Yehudar G Slama S Landes A Kneller M Leiba M Koren-Michowitz A Shimoni A Nagler 2008 Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies Clin Cancer Res 14 3044 3051 10.1158/1078-0432.CCR-07-4079 1:CAS:528:DC%2BD1cXmtVCmtbw%3D 18483370
15. H Nishimura T Honjo 2001 PD-1: an inhibitory immunoreceptor involved in peripheral tolerance Trends Immunol 22 265 268 10.1016/S1471-4906(01)01888-9 1:CAS:528:DC%2BD3MXktFahu7k%3D 11323285 (Pubitemid 32667515)
16. J Wang T Yoshida F Nakaki H Hiai T Okazaki T Honjo 2005 Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes Proc Natl Acad Sci USA 102 11823 11828 10.1073/pnas.0505497102 1:CAS:528:DC%2BD2MXpsFGgtb0%3D 16087865 (Pubitemid 41170809)
17. J Weber 2009 Ipilimumab: controversies in its development, utility and autoimmune adverse events Cancer Immunol Immunother 58 823 830 10.1007/s00262-008-0653-8 10.1007/s00262-008-0653-8 1:CAS:528: DC%2BD1MXit1CitLw%3D 19198837
18. GJ Hannon 2002 RNA interference Nature 418 244 251 10.1038/418244a 1:CAS:528:DC%2BD38XltFGmu7Y%3D 12110901 (Pubitemid 34773784)
19. WC Sha CA Nelson RD Newberry DM Kranz JH Russell DY Loh 1988 Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice Nature 335 271 274 10.1038/335271a0 1:CAS:528:DyaL1cXls1ymtrs%3D 3261843
20. TF Gajewski 1996 B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro J Immunol 156 465 472 1:CAS:528:DyaK28XksV2ltw%3D%3D 8543795
21. MT Spiotto P Yu DA Rowley MI Nishimura SC Meredith TF Gajewski YX Fu H Schreiber 2002 Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells Immunity 17 737 747 10.1016/S1074-7613(02)00480-6 1:CAS:528:DC%2BD38XpvVWgsLg%3D 12479820 (Pubitemid 35477793)
22. DM Kranz S Tonegawa HN Eisen 1984 Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes Proc Natl Acad Sci USA 81 7922 7926 10.1073/pnas.81.24.7922 1:CAS:528:DyaL2MXpsVSmtw%3D%3D 6334855 (Pubitemid 15169174)
23. M Toebes M Coccoris A Bins B Rodenko R Gomez NJ Nieuwkoop W van de Kasteele GF Rimmelzwaan JB Haanen H Ovaa TN Schumacher 2006 Design and use of conditional MHC class I ligands Nat Med 12 246 251 10.1038/nm1360 10.1038/nm1360 1:CAS:528:DC%2BD28XhtFajsrw%3D 16462803 (Pubitemid 43214754)
24. A Jorritsma R Gomez-Eerland M Dokter W van de Kasteele YM Zoet II Doxiadis N Rufer P Romero RA Morgan TN Schumacher JB Haanen 2007 Selecting highly affine and well-expressed TCRs for gene therapy of melanoma Blood 110 3564 3572 10.1182/blood-2007-02-075010 10.1182/blood-2007-02-075010 1:CAS:528:DC%2BD2sXhtlarur3E 17660381 (Pubitemid 350159623)
25. Gajewski TF, Markiewicz MA, Uyttenhove C (2001) The p815 mastocytoma tumor model. Curr Protoc Immunol. Chapter 20:Unit 20.4. doi: 10.1002/0471142735.im2004s43
26. N Selenko-Gebauer O Majdic A Szekeres G Hofler E Guthann U Korthauer G Zlabinger P Steinberger WF Pickl H Stockinger W Knapp J Stockl 2003 B7-h1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy J Immunol 170 3637 3644 1:CAS:528: DC%2BD3sXitFKlt7k%3D 12646628
27. K Udaka KH Wiesmuller S Kienle G Jung P Walden 1996 Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone J Immunol 157 670 678 1:CAS:528:DyaK28XktVynur8%3D 8752916
28. TR Brummelkamp R Bernards R Agami 2002 A system for stable expression of short interfering RNAs in mammalian cells Science 296 550 553 10.1126/science.1068999 1:CAS:528:DC%2BD38XjtFCjtrk%3D 11910072 (Pubitemid 34408678)
29. QJ Li J Chau PJ Ebert G Sylvester H Min G Liu R Braich M Manoharan J Soutschek P Skare LO Klein MM Davis CZ Chen 2007 miR-181a is an intrinsic modulator of T cell sensitivity and selection Cell 129 147 161 S0092-8674(07)00319-4 10.1016/j.cell.2007.03.008 1:CAS:528:DC%2BD2sXkvVeltLc%3D 17382377 (Pubitemid 46507589)
30. W Uckert TN Schumacher 2009 TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008 Cancer Immunol Immunother 58 809 822 10.1007/s00262-008-0649-4 10.1007/s00262-008-0649-4 1:CAS:528: DC%2BD1MXit1CitLg%3D 19189103